A5086171353- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Glycosylation and Glycoproteins Research
- Inflammatory Biomarkers in Disease Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- RNA modifications and cancer
- Radiomics and Machine Learning in Medical Imaging
- Nutrition and Health in Aging
- Esophageal Cancer Research and Treatment
- Infectious Diseases and Mycology
- Head and Neck Cancer Studies
- Brain Metastases and Treatment
- Pleural and Pulmonary Diseases
- Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Occupational and environmental lung diseases
- Cancer Research and Treatments
- Congenital Diaphragmatic Hernia Studies
- Immunotherapy and Immune Responses
- Cancer, Lipids, and Metabolism
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
Kyushu University
2016-2024
Dana-Farber Cancer Institute
2022-2024
Harvard University
2022-2024
National Hospital Organization Kyushu Cancer Center
2017-2022
Kyushu University Hospital
2022
Society of Thoracic Surgeons
2018
Saiseikai Fukuoka General Hospital
2014-2015
Abstract Programmed cell death‐1 ( PD ‐1) and programmed death‐ligand 1 ‐L1) have been identified as novel targets of immunotherapy lung cancer. In present study, we evaluated the metabolic characteristics cancer by using 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography F‐ FDG PET / CT ) with regard to ‐L1 protein expression. expression was immunohistochemistry antibody clone SP 142 in 579 surgically resected primary patients. Cases less than 5% tumor membrane...
Background: The prognostic Controlling Nutritional Status (CONUT) score is used to evaluate immuno-nutritional conditions and a predictive factor of postoperative survival in patients with digestive tract cancer. We retrospectively analyzed clinicopathological features pathological stage I non-small cell lung cancer (NSCLC) identify predictors or factors investigate the role preoperative CONUT predicting survival. Patients Methods: selected 138 consecutive NSCLC treated from August 2005...
Background: The preoperative immune-nutritional status has been shown to predict the postoperative prognosis in various types of cancer; however, prognostic significance controlling nutritional (CONUT) score resected lung squamous cell carcinoma (SCC) yet be elucidated. Methods: A total 108 patients with SCC were analyzed for their clinicopathological factors, including CONUT score, which can calculated from serum albumin, cholesterol, and peripheral lymphocyte count. divided into two...
Immunotherapy targeting programmed cell death-1 (PD-1) and death-ligand 1 (PD-L1) has become the forefront strategy for systemic therapy in advanced non-small lung cancer (NSCLC) patients. PD-L1 expression on tumor cells been reported as an eligible biomarker of response to such immunotherapies. However, useful biomarkers atezolizumab, anti antibody, are unestablished.We retrospectively analyzed clinicopathological characteristics including NSCLC patients treated with atezolizumab from...
Abstract The long non-coding RNA X-inactive specific transcript (lncRNA XIST) and MUC1 gene are dysregulated in chronic inflammation cancer; however, there is no known interaction of their functions. present studies demonstrate that MUC1-C regulates XIST lncRNA levels by suppressing the RBM15/B, WTAP METTL3/14 components m6A methylation complex associate with A repeats. also suppresses YTHDF2-CNOT1 deadenylase recognizes sites contributes to decay increases stability expression. In support...
The world's population is rapidly ageing, and the age of patients with lung cancer will increase as well. prognostic nutritional index, controlling status geriatric risk index (GNRI) are useful parameters for evaluating immune-nutritional status. We aimed to perform a multicentre retrospective study investigate correlations these postoperative comorbidities or surgical outcomes elderly non-small-cell (NSCLC).We selected 272 consecutive NSCLC aged >75 years treated from January 2005 December...
The MUC1-C protein evolved in mammals to protect barrier tissues from loss of homeostasis; however, promotes oncogenesis association with chronic inflammation. Aberrant expression cancers has been linked depletion and dysfunction T cells the tumor microenvironment. In contrast, there is no known involvement regulation natural killer (NK) cell function.Targeting genetically pharmacologically cancer was performed assess effects on intracellular surface MHC class I chain-related polypeptide A...
There are great expectations for artificial intelligence (AI) in medicine. We aimed to develop an AI prognostic model surgically resected non-small cell lung cancer (NSCLC). This study enrolled 1049 patients with pathological stage I-IIIA NSCLC at Kyushu University. set 17 clinicopathological factors and 30 preoperative 22 postoperative blood test results as explanatory variables. Disease-free survival (DFS), overall (OS), cancer-specific (CSS) were objective The eXtreme Gradient Boosting...
IntroductionOsimertinib is an irreversible EGFR tyrosine kinase inhibitor approved for the first-line treatment of patients with metastatic NSCLC harboring exon 19 deletions or L858R mutations. Patients treated osimertinib invariably develop acquired resistance by mechanisms involving additional mutations, MET amplification, and other pathways. There no known involvement oncogenic MUC1-C protein in resistance.MethodsH1975/EGFR (L858R/T790M) patient-derived cells were investigated dependence...
Abstract The oncogenic MUC1-C transmembrane protein is a critical effector of the cancer stem cell (CSC) state. Addiction to for self-renewal in progression human cancers has emphasized need development anti-MUC1-C agents. However, there are presently no approved small molecules targeting MUC1-C-dependent CSCs. In screening molecules, we identified salinomycin (SAL), an inducer ferroptosis, as potent inhibitor signaling. We demonstrate that SAL suppresses expression by disrupting...
Abstract The MUC1 gene evolved in mammals for adaptation of barrier tissues response to infections and damage. Paraspeckles are nuclear bodies formed on the NEAT1 lncRNA loss homeostasis. There is no known intersection with or paraspeckles. Here, we demonstrate that MUC1-C subunit plays an essential role regulating expression. activates induction NEAT1_1 NEAT1_2 isoforms by NF-κB- MYC-mediated mechanisms. MUC1-C/MYC signaling also induces expression SFPQ, NONO FUS RNA binding proteins (RBPs)...
Although the skeletal muscle in region of third lumbar vertebra (L3) is generally assessed order to judge sarcopenia, not every patient with non-small cell lung cancer (NSCLC) undergoes computed tomography including L3 region. We hypothesized that immuno-nutritional parameters could predict existence sarcopenia patients NSCLC.The aim this study was retrospectively investigate correlation between preoperative and early-stage NSCLC.We selected 147 pathological stage I NSCLC who underwent...
Abstract The polybromo-1 (PBRM1) chromatin-targeting subunit of the SWI/SNF PBAF chromatin remodeling complex drives DNA damage resistance and immune evasion in certain cancer cells through mechanisms that remain unclear. STAT1 IRF1 are essential effectors type I II IFN pathways. Here, we report MUC1-C is necessary for PBRM1 expression it forms a nuclear with triple-negative breast (TNBC) cells. Analysis global transcriptional (RNA-seq) accessibility (ATAC-seq) profiles further demonstrated...
Background/Aim: Few studies have so far described the conversion of programmed death-ligand 1 (PD-L1) after treatment. In particular, effect nivolumab on PD-L1 expression has never been reported. We investigated changes in chemotherapy and treatment herein describe detailed clinical course. Patients Methods: retrospectively examined resected specimens re-biopsy patients with non-small cell lung cancer by immunohistochemical analysis. Results: Four underwent a Of those, three showed positive...
Pembrolizumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody, has been shown to yield a durable response and significant survival benefit in some non-small lung cancer (NSCLC) patients. Recent studies have that the Controlling Nutritional Status (CONUT) score, novel nutritional index, can be useful for predicting prognosis malignancies. However, its usefulness clinical outcome of immune-checkpoint inhibitor (ICI) treatment patients with NSCLC not clarified. The aim this study...